Clinical Trial

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colorectal cancer or colorectal liver metastases (CRLM) who have measurable residual disease (MRD) after standard treatment with surgery and chemotherapy or total neoadjuvant therapy (TNT).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-11-10; most recent amendment 2026-02-04.
Trial Details
NCT Number NCT07227636
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Agenus Inc.
Conditions Colorectal Cancer, Rectal Cancer
Enrollment 284 participants
Start Date 2025-11-07
Primary Completion 2030-11 (estimated)
Study Completion 2030-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-06